Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
Barnes Group Inc. (NYSE: B) maintains its position as a global leader in precision industrial technologies and aerospace solutions. This news hub provides investors and industry professionals with essential updates on corporate developments, financial performance, and strategic initiatives.
Access timely updates spanning earnings announcements, product innovations, and operational milestones. Our curated collection features official press releases alongside market analysis relevant to Barnes Grp's industrial and aerospace segments.
Key coverage areas include manufacturing advancements in transportation systems, aerospace component developments, and strategic partnerships across global markets. The repository serves as a reliable resource for understanding the company's impact on sectors ranging from healthcare infrastructure to defense technologies.
Bookmark this page for streamlined access to Barnes Grp's latest financial disclosures and operational updates. Regularly refreshed content ensures stakeholders maintain current awareness of this engineering leader's market position and technological contributions.
Barrick Mining (NYSE:B) has announced the sale of its Hemlo Gold Mine in Canada to Carcetti Capital Corp. (to be renamed Hemlo Mining Corp.) for up to $1.09 billion. The deal structure includes $875 million in cash, $50 million in HMC shares, and potential additional payments of up to $165 million linked to production and gold prices starting January 2027.
HMC is led by experienced mining executive Robert Quartermain and backed by Wheaton Precious Metals and Orion Mine Finance Management. The transaction, expected to close in Q4 2025, is part of Barrick's strategy to focus on its Tier One gold and copper portfolio, with total proceeds from non-core asset sales expected to exceed $2 billion this year.
BioArctic (NASDAQ STOCKHOLM: BIOA B) announced that CEO Gunilla Osswald has been named Uppsala University's Alumnus of the Year 2025. The recognition highlights her exemplary leadership and contributions to scientific innovation, particularly in the development of lecanemab for Alzheimer's disease.
Earlier in March 2025, Osswald and BioArctic's founders were also awarded the university's Innovation and Entrepreneurship Prize. The university praised her visionary and inclusive leadership style, noting her ability to foster collaboration and serve as a role model for women in science and technology.
Integrum AB (INTEG B) unveiled its new global marketing strategy at the AOPA National Assembly in Orlando, introducing BondedMatrix™, a term describing the OPRA™ Implant System's unique capability to integrate soft tissue and bone. The strategy aims to better communicate the system's distinct advantages in bone-anchored prosthetics.
The OPRA™ Implant System, invented by Dr. Rickard Brånemark, has been refined since 1990 and has been used in over 1,000 implants worldwide. BondedMatrix™ specifically refers to the biologically integrated barrier connecting skin and bone at the penetration site, a unique feature achieved through OPRA's surgical technique and implant design.
BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has initiated a rolling submission of a Supplemental Biologics License Application (sBLA) to the FDA for Leqembi Iqlik's subcutaneous autoinjector as a weekly starting dose for early Alzheimer's disease treatment. This follows the recent approval of Leqembi Iqlik for maintenance dosing in the US on August 29, 2025.
If approved, Leqembi Iqlik would become the first anti-amyloid treatment offering at-home injection from start to maintenance. The proposed dosing regimen includes 500 mg SC dosing (two 250 mg injections) weekly, as an alternative to bi-weekly intravenous dosing. The autoinjector requires only 15 seconds per injection and could potentially reduce healthcare resources associated with IV administration.
Leqembi, currently approved in 48 countries and under review in 10 others, uniquely targets both amyloid plaque and protofibrils in Alzheimer's disease treatment.
Integrum AB (Nasdaq First North: INTEG B) has scheduled its first quarter 2025/26 results presentation for September 1, 2025, at 10:00 CET. The presentation will be conducted via webcast, featuring CEO Martin Hillsten and CFO Jörgen Svanström presenting the quarterly report in English.
The report and presentation materials will be accessible through the company's investor relations website and the Finwire.tv platform, where participants will have the opportunity to ask questions during the session.
Helzberg, a subsidiary of Berkshire Hathaway (NYSE:BRK), has announced a national partnership with Big Brothers Big Sisters of America (BBBSA) ahead of Big Brothers Big Sisters Month in September 2025. The collaboration combines financial investment, volunteer engagement, and career exploration opportunities to enhance youth mentorship nationwide.
The partnership launched in Kansas City with BBBSA's Diamond Anniversary celebration at Kauffman Stadium and will continue with various events including a special gathering at the KC Current match on August 30. Helzberg's nationwide network of associates will participate in volunteer efforts including career day mentoring and Pack + Give Back events across key markets.
BioArctic (Nasdaq Stockholm: BIOA B) has entered into a significant collaboration agreement with Novartis Pharma AG to develop potential neurodegeneration treatments using BioArctic's proprietary BrainTransporter technology. The deal includes an upfront payment of $30 million to BioArctic.
Under the agreement, BioArctic will develop a new drug candidate combining their BrainTransporter technology with Novartis' proprietary antibody. If Novartis exercises their option following evaluation, they could pay up to $772 million in additional milestone payments plus mid-single digit royalties on future global sales. This marks BioArctic's third partnership utilizing their BrainTransporter platform, which enhances brain uptake of therapeutic agents through blood-brain barrier biology.
BioArctic AB (NASDAQ Stockholm: BIOA B) announced the EU launch of Leqembi®, the first therapy targeting an underlying cause of Alzheimer's disease, starting in Austria on August 25, 2025, and Germany on September 1, 2025.
The drug, approved by the European Commission in April 2025, is indicated for adult patients with mild cognitive impairment and mild dementia due to early Alzheimer's disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology. In clinical trials, Leqembi demonstrated a 31% reduction in clinical decline at 18 months compared to placebo in the EU indicated population.
The treatment uniquely targets both amyloid plaque and protofibrils, potentially impacting tau accumulation. Common adverse reactions include infusion-related reactions (26%), ARIA-H (13%), headache (11%), and ARIA-E (9%).
BioArctic AB (NASDAQ Stockholm: BIOA B) has announced the upcoming release of its Q2 2025 financial report on August 28, 2025, at 08:00 a.m. CET. The company will host an audiocast with teleconference in English at 09:30 CET featuring CEO Gunilla Osswald, CFO Anders Martin-Löf, and other executives who will present and discuss the quarterly results.
The presentation will be accessible via webcast and teleconference, with opportunities for participants to ask questions either written or verbally. The webcast recording will be available on-demand through BioArctic's corporate website after the event.
ETQ, a division of Hexagon (HEXA), has been shortlisted for the 2025 A.I. Awards in the Best Use of AI in Manufacturing category. The recognition comes for their ETQ Reliance® Predictive Quality Analytics (PQA) solution, developed in partnership with Acerta.
The PQA solution leverages machine learning to analyze manufacturing data, detect potential defects early, and provide proactive solutions to quality issues. The AI-driven system helps manufacturers improve operational efficiency, ensure compliance, and manage risk by identifying production problems earlier and enabling faster resolution.
FAQ
What is the current stock price of Barrick Mining Corporation (B)?
What is the market cap of Barrick Mining Corporation (B)?
